Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stock Report

Mkt Cap: US$195.2m

We’ve recently updated our valuation analysis.

Y-mAbs Therapeutics Valuation

Is YMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YMAB?

Other financial metrics that can be useful for relative valuation.

YMAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA-0.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does YMAB's PS Ratio compare to its peers?

The above table shows the PS ratio for YMAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.4x
URGN UroGen Pharma
3.1x36.3%US$194.0m
ADAP Adaptimmune Therapeutics
16x42.7%US$280.1m
SELB Selecta Biosciences
2.1x-3.8%US$261.7m
PRE Prenetics Global
0.6x17.4%US$172.0m
YMAB Y-mAbs Therapeutics
4.5x21.7%US$195.2m

Price-To-Sales vs Peers: YMAB is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (5.4x).


Price to Earnings Ratio vs Industry

How does YMAB's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Sales vs Industry: YMAB is good value based on its Price-To-Sales Ratio (4.5x) compared to the US Biotechs industry average (13x)


Price to Sales Ratio vs Fair Ratio

What is YMAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YMAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ratio6.4x

Price-To-Sales vs Fair Ratio: YMAB is good value based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (6.4x).


Share Price vs Fair Value

What is the Fair Price of YMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate YMAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate YMAB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst YMAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.47
US$10.88
+143.3%
51.3%US$20.00US$5.00n/a8
Jan ’24US$4.88
US$11.88
+143.3%
57.0%US$23.00US$4.00n/a8
Dec ’23US$4.50
US$14.75
+227.8%
52.3%US$27.00US$4.00n/a8
Nov ’23US$3.35
US$15.00
+347.8%
49.2%US$27.00US$6.00n/a8
Oct ’23US$14.42
US$29.38
+103.7%
47.8%US$63.00US$16.00n/a8
Sep ’23US$16.01
US$29.13
+81.9%
49.0%US$63.00US$15.00n/a8
Aug ’23US$15.26
US$28.88
+89.2%
49.3%US$63.00US$15.00n/a8
Jul ’23US$15.34
US$27.71
+80.7%
54.2%US$63.00US$15.00n/a7
Jun ’23US$12.67
US$27.83
+119.7%
58.3%US$63.00US$15.00n/a6
May ’23US$8.40
US$29.33
+249.2%
54.8%US$63.00US$15.00n/a6
Apr ’23US$13.06
US$31.83
+143.7%
51.7%US$63.00US$15.00n/a6
Mar ’23US$9.29
US$33.50
+260.6%
45.8%US$63.00US$15.00n/a6
Feb ’23US$10.00
US$41.40
+314.0%
45.0%US$68.00US$15.00n/a5
Jan ’23US$16.21
US$45.60
+181.3%
37.0%US$68.00US$25.00US$4.885
Dec ’22US$16.04
US$46.20
+188.0%
35.1%US$68.00US$25.00US$4.505
Nov ’22US$26.08
US$55.33
+112.2%
14.5%US$68.00US$41.00US$3.356
Oct ’22US$29.31
US$55.33
+88.8%
14.5%US$68.00US$41.00US$14.426
Sep ’22US$32.87
US$55.57
+69.1%
13.4%US$68.00US$41.00US$16.017
Aug ’22US$33.10
US$55.71
+68.3%
12.9%US$68.00US$42.00US$15.267
Jul ’22US$35.13
US$56.88
+61.9%
13.0%US$68.00US$42.00US$15.348
Jun ’22US$35.04
US$57.13
+63.0%
13.6%US$70.00US$42.00US$12.678
May ’22US$30.07
US$56.75
+88.7%
12.9%US$70.00US$45.00US$8.408
Apr ’22US$30.28
US$58.63
+93.6%
13.3%US$70.00US$45.00US$13.068
Mar ’22US$35.72
US$59.25
+65.9%
12.5%US$70.00US$45.00US$9.298
Feb ’22US$42.53
US$60.13
+41.4%
12.3%US$71.00US$45.00US$10.008
Jan ’22US$49.51
US$58.88
+18.9%
12.8%US$71.00US$45.00US$16.218

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies